Finanzen von Health Catalyst Inc (HCAT)HCATHealth Catalyst Inc

Health Catalyst, Inc. (HCAT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Recurring technology, accounting for 69.2% of total sales, equivalent to $48.80M. Another important revenue stream is Professional Services. Understanding this composition is critical for investors evaluating how HCAT navigates market cycles within the Software industry.

Evaluating the bottom line, Health Catalyst, Inc. maintains a gross margin of 34.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5.35%, while the net margin is -57.51%. These profitability ratios, combined with a Return on Equity (ROE) of -118.12%, provide a clear picture of how effectively HCAT converts its operational activities into shareholder value.

In the context of the broader market, HCAT competes directly with industry leaders such as ATGL and DH. With a market capitalization of $128.69M, it holds a significant position in the sector. When comparing efficiency, HCAT's gross margin of 34.64% stands against ATGL's 48.15% and DH's 57.97%. Such benchmarking helps identify whether Health Catalyst, Inc. is trading at a premium or discount relative to its financial performance.

Health Catalyst has shown a troubling trend with a net income loss of $111 million in Q1 2026 and a gross margin of only 33.46%. The company has also seen a significant decline in total revenue, with Q2 2026 revenue at $70.49 million, down from $79.61 million in Q4 2024.